Finanzen von Arcutis Biotherapeutics, Inc. (ARQT)ARQTArcutis Biotherapeutics, Inc.

Evaluating the bottom line, Arcutis Biotherapeutics, Inc. maintains a gross margin of 91.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.65%, while the net margin is 11.56%. These profitability ratios, combined with a Return on Equity (ROE) of 15.86%, provide a clear picture of how effectively ARQT converts its operational activities into shareholder value.

In the context of the broader market, ARQT competes directly with industry leaders such as OGN and LEGN. With a market capitalization of $4.01B, it holds a leading position in the sector. When comparing efficiency, ARQT's gross margin of 91.58% stands against OGN's 54.01% and LEGN's 64.54%. Such benchmarking helps identify whether Arcutis Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

In Q2 2026, Arcutis reported total revenue of $129.86 million, a substantial increase from $81.50 million in the previous year, driven by strong demand for its ZORYVE products. The company has also raised its full-year 2026 net product sales guidance to between $525 million and $540 million, reflecting confidence in future performance.